SEATTLE--(BUSINESS WIRE)--Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system. The platform offers a revolutionary leap toward rapid risk stratification for acute myeloid leukemia (AML)..

SEATTLE-（BUSINESS WIRE）-Phase Genomics，Inc.是行业领先的基因组解决方案的全球创新者，今天宣布在领先的AVITI上展示基于OncoTerra cytogenomics平台的邻近连接测序的新数据。新一代测序系统。该平台为急性髓性白血病（AML）的快速风险分层提供了革命性的飞跃。。

Traditional cytogenetics has relied on a battery of assays for comprehensive evaluation, including karyotyping, FISH, and CMA, identifying large-scale structural alterations in chromosomes. Not only do these tests often fail to detect clinically relevant sub-microscopic variations, the cascade approach prolongs the time from sample collection to actionable insight..

传统的细胞遗传学依赖于一系列用于综合评估的测定，包括核型分析，FISH和CMA，鉴定染色体中的大规模结构改变。这些测试不仅经常无法检测到临床相关的亚微观变化，级联方法还将从样品收集到可行的见解的时间延长了。。

Phase Genomics addresses these legacy challenges with the combination of its OncoTerra technology and Element’s AVITI system for next-generation sequencing, providing a high-resolution alternative for comprehensive, streamlined risk stratification in the research setting. OncoTerra on AVITI has demonstrated detection of the full range of chromosomal abnormalities observed in cancer from sample to cytogenomic insights..

Phase Genomics通过将OncoTerra技术和Element的AVITI系统结合用于下一代测序，解决了这些遗留挑战，为研究环境中全面，简化的风险分层提供了高分辨率的替代方案。AVITI上的OncoTerra已证明可以从样本到细胞基因组学见解检测癌症中观察到的所有染色体异常。。

“Our results speak to the real potential of OncoTerra on the AVITI sequencer. The next-generation cytogenomics all-in-one approach is primed to replace fragmented legacy tests with a single, rapid assay,” said Ivan Liachko, founder and CEO of Phase Genomics. “The ability to uncover previously undetected structural alterations in AML opens the exploration for new avenues for targeted therapies and personalized medicine.

“我们的研究结果说明了OncoTerra在AVITI测序仪上的真正潜力，下一代细胞基因组学一体化方法已经准备好用单一的快速检测方法取代碎片化的遗留检测，”Phase Genomics的创始人兼首席执行官Ivan Liachko说。“发现AML以前未发现的结构改变的能力为靶向治疗和个性化医疗开辟了新途径。

OncoTerra on AVITI represents a major stride toward accelerating cancer diagnoses and improving patient outcomes.”.

AVITI上的OncoTerra代表了加速癌症诊断和改善患者预后的重大步伐。

The research leveraged OncoTerra for de novo risk assessment of 32 AML patient samples in the retrospective setting. Utilizing proximity ligation sequencing, OncoTerra delivered exceptional proficiency in detecting structural aberrations directly within AML samples, as well as seven variants of known clinical significance not detected by standard-of-care cytogenetic testing.

该研究利用OncoTerra在回顾性环境中对32例AML患者样本进行从头风险评估。利用邻近连接测序，OncoTerra在直接检测AML样品内的结构畸变方面提供了出色的熟练程度，以及通过标准护理细胞遗传学测试未检测到的七种已知临床意义的变体。

These alterations included sub-microscopic inversions, terminal translocations, insertions, and copy-neutral loss of heterozygosity. The increased resolution and integrated analysis of the genome using OncoTerra yielded additional findings in eleven cases without previously detected chromosome abnormalities..

这些改变包括亚微观倒位，末端易位，插入和杂合性的复制中性丧失。使用OncoTerra提高的分辨率和对基因组的综合分析在11例以前未检测到染色体异常的病例中产生了其他发现。。

The study also highlighted the improved efficiency and read quality of the AVITI sequencer compared to other platforms. Benchmarking AVITI against Illumina NovaSeq platforms revealed a 20% enhancement in the fraction of effective read pairs, indicating greater sequencing efficiency and coverage.

该研究还强调了与其他平台相比，AVITI测序仪的效率和读取质量得到了提高。针对Illumina NovaSeq平台对AVITI进行基准测试显示，有效读取对的比例提高了20%，表明测序效率和覆盖率更高。

Phase Genomics, the recent recipient of the Biotech Breakthrough Award for Metagenomics Innovation Of The Year, will highlight the power of OncoTerra for AML in poster G025, “Next-generation cytogenomics using proximity ligation technology on the AVITI genome sequencing platform” on November 18. Discover more about next-generation cytogenomics powered by proximity ligation technology in four presentations at AMP23, or connect with the Phase Genomics team at Booth 810..

Phase Genomics是今年宏基因组学创新生物技术突破奖的最新获得者，将于11月18日在海报G025“在AVITI基因组测序平台上使用邻近连接技术的下一代细胞基因组学”中突出OncoTerra对AML的作用。在AMP23的四次演示中发现更多关于由邻近连接技术支持的下一代细胞基因组学的信息，或与810展位的Phase Genomics团队联系。。

OncoTerra is available for research use only and is not for use as a clinical diagnostic.

OncoTerra仅供研究使用，不能用作临床诊断。

Follow Phase Genomics on X (formerly Twitter) and LinkedIn for the latest company news and information.

遵循X（以前的Twitter）上的Phase Genomics和LinkedIn的最新公司新闻和信息。

ABOUT PHASE GENOMICS

关于阶段基因组学

Phase Genomics applies proprietary proximity ligation technology to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture. In addition to a comprehensive portfolio of laboratory and computational services and products, including Hi-C kits for plants, animals, microbes, and human samples, they also offer an industry-leading genome and metagenome assembly and analysis software..

Phase Genomics应用专有的邻近连接技术来实现染色体规模的基因组组装，宏基因组去卷积，以及结构基因组变异和基因组结构的分析。除了全面的实验室和计算服务和产品组合，包括用于植物，动物，微生物和人类样品的Hi-C试剂盒，他们还提供行业领先的基因组和宏基因组组装和分析软件。。

Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

该公司总部设在华盛顿州西雅图市，成立于2015年，由基因组科学家，软件工程师和企业家组成。该公司的使命是为科学家提供基因组工具，以加速突破性发现。